Article Sidebar

PDF
Date Published: 15/03/2024
Abstract Views: 178
Views PDF: 126
DOI: https://doi.org/10.51298/vmj.v536i1B.8750
Issue
Vol. 536 No. 1B (2024)
Section
Các bài báo
How to Cite
Nguyễn , T. D., Cấn, X. H. ., Nguyễn , T. L., & Đặng , T. L. . (2024). EVALUATE SURVIVAL TIME OF STAGE IV NON- SMALL CELL LUNG CANCER PATIENTS TREATED BY PEMBROLIZUMAB COMBINED WITH CHEMOTHERAPY AT NATIONAL LUNG HOSPITAL. Vietnam Medical Journal, 536(1B). https://doi.org/10.51298/vmj.v536i1B.8750

EVALUATE SURVIVAL TIME OF STAGE IV NON- SMALL CELL LUNG CANCER PATIENTS TREATED BY PEMBROLIZUMAB COMBINED WITH CHEMOTHERAPY AT NATIONAL LUNG HOSPITAL

Thanh Dương Nguyễn , Xuân Hạnh Cấn, Thành Lâm Nguyễn , Thùy Linh Đặng

Main Article Content

Abstract

Objective: Evaluation of survival time in patients with stage IV non-small cell lung cancer treated with Pembrolizumab regimen combined with chemotherapy. Methods: Cross-sectional descriptive study combined with retrospective with longitudinal follow-up on 63 patients with stage IV non-small cell lung cancer treated with Pembrolizumab regimen combined with chemotherapy at the National Lung Hospital. Implementation period is from June 2019 to June 2023. Results: Patients with stage IV non-small cell lung cancer treated with the Pembrolizumab regimen combined with chemotherapy had a median progression-free survival of 10.91 ± 2.22 months (95%CI: 6.52-15.30). The progression-free survival time between the group with PD-L1 expression was higher than the group without PD-L1 expression, this difference was statistically significant with p = 0.04 < 0.05. Conclusion: Pembrolizumab regimen combined with chemotherapy improves survival time in patients with stage IV non-small cell lung cancer.

Article Details

References

1. Thandra K.C, Barsouk A, Saginala K et al (2021). Epidemiology of lung cancer. Contemp Oncol (Pozn), 25(1), 45-52.
2. Gadgeel S, Rodríguez-Abreu D, Speranza G et al (2020). Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol, 38(14), 1505-1517.
3. Robinson AG, Vicente D., Tafreshi A et al (2021). First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407. J Thorac Oncol, 16(14):S748-S749.
4. Trinh Le Huy, Tran Dinh Anh (2022). Efficacy and safety of pembrolizumab monotherapy in advanced non-small cell lung cancer patients treated at Hanoi Medical University Hospital. Tạp chí Nghiên cứu Y học, 154(6), 146-152.
5. Hàn Thị Thanh Bình (2014). So Sánh Đáp Ứng và Độc Tính Hoá Chất Phác Đồ Paclitaxel-Cisplatin và Etoposide-Cisplatin Trên Bệnh Nhân Ung Thư Phổi Không Tế Bào Nhỏ Giai Đoạn Tiến Triển Tại Chỗ và Di Căn Xa, Luận án Tiến sĩ Y học, Đại học Y Hà Nội.
6. Nguyễn Việt Hà, Nguyễn Tuyết Mai (2021). Kết quả điều trị ung thư phổi không tế bào nhỏ giai đoạn IIIB-IV bằng phác đồ Pemetrexed-Cisplatin. Tạp chí Y học Việt nam, Tập 501, Tháng 4 - Số 1, tr. 264 - 268.